enGene Holdings Inc. announced the issuance of 2026 Closing Date Warrants to purchase common shares. The warrants were issued in connection with a loan agreement, with an aggregate of 40,850 warrants issued to lenders on the closing date. Each warrant has an exercise price of $9.18 per share and is exercisable for seven years from issuance. The total maximum number of 2026 Warrants that may be issued under the agreement is 204,248, representing 1.50% of the total loan commitment amount divided by the exercise price. The transaction was conducted as an unregistered sale of equity securities pursuant to Section 4(a)(2) of the Securities Act of 1933.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. enGene Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-017945), on January 21, 2026, and is solely responsible for the information contained therein.
Comments